Dub Therapeutics Inc.
Publicly observedSyracuse, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Syracuse | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Dub Therapeutics Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | RNZAEDZ7WJG2 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Sept 2025Publicly observed
NIH SBIR/STTR award: A novel siRNA therapeutic to prevent scarring and bleb failure after trabeculectomy
USD 1,009,284.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
- Grant15 Sept 2025Publicly observed
NIH SBIR/STTR award: A novel siRNA therapeutic to prevent scarring and bleb failure after trabeculectomy
USD 1,009,285.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.